Close Menu

NYGC

The company, Gencove, was founded by the developers of a consumer-focused, smartphone-accessible genetic testing program launched in beta as Seeq.

In PNAS this week: analytical method for assessing shared variants, treatment targets in hereditary pancreatic cancer, and more.

The scientists aim to better understand a phenomenon where the severity of effects of a particular genetic mutation differs among individuals who carry it.

PlayDNA Pilot Project

The New York Genome Center spinout has been conducting a pilot project involving Oxford Nanopore's MinIon with a Manhattan middle school.

The Israeli institute will share its expertise on translating research into commercially viable applications with the goal of advancing personalized medicine.

The centers are using the standardized pipeline to help streamline data sharing and data analysis to achieve their larger research goals.

The researchers applied their so-called GWAX approach to study 12 common diseases in almost 120,000 individuals, confirming known and uncovering novel disease risk loci.

The center plans to offer the test for patients with undiagnosed disease and for disease predisposition testing in ostensibly healthy individuals.

The partners have committed to analyzing coding mutations, driver non-coding mutations, and structural variations across tumor types for the project.

Seeq has much in common with DNA.Land, launched last year, but targets individuals who have not used services from direct-to-consumer testing companies

Pages

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.